Ann Elizabeth Stanger, MD | |
2984 Triverton Pike Dr, Fitchburg, WI 53711-5841 | |
(608) 233-2378 | |
(608) 233-2375 |
Full Name | Ann Elizabeth Stanger |
---|---|
Gender | Female |
Speciality | General Practice |
Location | 2984 Triverton Pike Dr, Fitchburg, Wisconsin |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1154491298 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208D00000X | General Practice | 31332 (Wisconsin) | Primary |
Mailing Address | Practice Location Address |
---|---|
Ann Elizabeth Stanger, MD 2984 Triverton Pike Dr, Fitchburg, WI 53711-5841 Ph: (608) 233-2378 | Ann Elizabeth Stanger, MD 2984 Triverton Pike Dr, Fitchburg, WI 53711-5841 Ph: (608) 233-2378 |
News Archive
In a Kaiser Health News companion piece to the story, Some Hill Races Could Hinge On Seniors' Anger Over Medicare, Marilyn Werber Serafini reports that Wisconsin Rep. Paul Ryan's ideas - including giving Medicare beneficiaries a voucher to buy health coverage and adjusting benefits based on income - could gain ground if the GOP wins control of the House in November (Serafini, 10/26).
The diabetes population in the United States will almost double over the next 25 years and annual medical spending on the disease is projected to hit $336 billion, up from $113 billion today, according to a study published in the December issue of Diabetes Care. The National Changing Diabetes® Program (NCDP), a program of Novo Nordisk, commissioned the analysis by a team from the University of Chicago.
"Every cancer diagnosis should come with a referral to genetic counseling," says cancer expert Dr. Antonio Giordano, President of the Sbarro Health Research Organization at Temple University.
Trovagene, Inc., a developer of cell-free molecular diagnostics, announced today that it has entered into an agreement with FedMed, Inc. establishing health benefit access to Trovagene's full line of Precision Cancer Monitoring (PCM) tests and services.
The Redsense safety device is the only device cleared by FDA to monitor patients for potential blood loss from the hemodialysis needle puncture site. With an 8 hour FDA clinical clearance, Redsense is available to help protect patients undergoing treatment in clinics for longer than 5 hours - such as Nocturnal Dialysis.
› Verified 8 days ago